Stage I placental site trophoblastic tumor with complete response after pembrolizumab

Gynecologic Oncology Reports 2026 Open access

Read full text
Authors: Pierre Descargues, Lua Ruhiyyih Eiriksson, Pascal Rousset, Adrien Msika, Benoît You, Alexis Trécourt, Jérôme Massardier, Touria Hajri, Bruno Borghese, François Golfier, Pierre‐Adrien Bolze, Jérôme Alexandre
DOI: 10.1016/j.gore.2026.102023
Cited by: 0
References: 14

Abstract

• Placental site trophoblastic tumors (PSTT) express programmed cell death ligand 1 (PD-L1) making them an ideal target for programmed cell death receptor 1 (PD-1) and PD-L1 inhibitors. • In a patient with PSTT desirous of fertility-sparing treatment, a complete response with PD-1 inhibition has been demonstrated with sustained response. • Despite the potential toxicity of PD-1 inhibition, there is potential for significant benefit, especially in the absence of alternative fertility-sparing treatment options for patients with PSTT.

Fields of Study & Subjects

Gestational Trophoblastic Disease Studies Pregnancy and preeclampsia studies Cancer Risks and Factors

Publication details

Journal / source
Gynecologic Oncology Reports
Volume
63
Pages
102023–102023
Publication date
5 January 2026
Language
EN